Salim Yusuf - Concepedia

Author

Salim Yusuf

Also Known As

, Ahn, Sylvie, Anne-Katrin Giese, Below, Jennifer E., Benedict, Claude, Chiou, Joshua, Christoph Wanner, Daniel I. Sessler, Denis Angoulvant, Dr. Shamima Yusuf

2.2K

Publications

314.9K

Citations

265

H-Index

451

Concepts

All Affiliations

McMaster University Population Health Research Institute Hamilton Health Sciences Chinese Academy of Medical Sciences & Peking Union Medical College Universidad de La Frontera

About

Salim Yusuf is an author at McMaster University specializing in medicine, cardiovascular disease, and public health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	30	46	7.8K
2	Engineering	14	18	1.6K
3	Business	3	3	175
4	Education	2	2	409
5	Language Studies	1	1	297

Salim Yusuf

992

Publications

228.7K

Citations

221

H-Index

Page 1

	Year	Citations
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Salim Yusuf, Steven Hawken, Stephanie Ôunpuu, The Lancet Cardiovascular EpidemiologyCardiovascular DiseaseDisease Risk AssessmentGlobal HealthInterheart Study	2004	11.8K
Dabigatran versus Warfarin in Patients with Atrial Fibrillation Stuart J. Connolly, Michael D. Ezekowitz, Salim Yusuf, New England Journal of Medicine	2009	11.1K
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study Martin O’Donnell, Denis Xavier, Lisheng Liu, The Lancet Cerebrovascular DiseaseCase-control StudyThrombosisStrokeBrain Injury	2010	3.4K
COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS Robert Altman, L Carreras, Rubén Sierra Díaz, Oxford University Research Archive (ORA) (University of Oxford) ThrombosisIschemic StrokeCardiovascular DiseaseMedicineBlood Platelet	1994	3.3K
Beta blockade during and after myocardial infarction: An overview of the randomized trials Salim Yusuf, Richard Peto, John A. Lewis, Progress in Cardiovascular Diseases Percutaneous Coronary InterventionThrombosisCardiovascular DiseaseClinical TrialsRandomized Trials	1985	3.2K
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial Salim Yusuf, Marc A. Pfeffer, Karl Swedberg, The Lancet Left-ventricular Ejection FractionHeart FailureChronic Heart FailureCardiovascular DiseaseCardiovascular Pharmacology	2003	2.9K
Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study Salim Yusuf, Steven Hawken, Stephanie Ôunpuu, The Lancet ObesityMetabolic SyndromeCardiovascular EpidemiologyCardiovascular DiseaseHealth Policy	2005	2.9K
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Shamir R. Mehta, Salim Yusuf, Ron J.G. Peters, The Lancet Percutaneous Coronary InterventionThrombosisPci-cure StudyCardiovascular DiseaseCoronary Artery Disease	2001	2.8K
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial John J.V. McMurray, Jan Östergren, Karl Swedberg, The Lancet HypertensionHeart FailureChronic Heart FailureCharm-added TrialCardiovascular Disease	2003	2.6K
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Shamir R. Mehta, Salim Yusuf, Ron J.G. Peters ACC Current Journal Review Percutaneous Coronary InterventionThrombosisPci-cure StudyCardiovascular DiseaseCoronary Artery Disease	2002	2.6K

Page 1